Zinc Supplement

Phase 3Small molecule

HHamilton Health Sciences Corporation

Zinc Supplement is one of 57 small molecule programs targeting Oral Lichen Planus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oral Lichen PlanusActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Oral Lichen PlanusPreclinical

Active, not recruiting

Chronic Kidney DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Aranesp

Amgen

Preclinical

40 2

Zinc Supplement

HHamilton Health Sciences Corporation

Phase 3

1 3

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 4

Uloric

Takeda

Preclinical

3 5

Sovaldi

Gilead

Preclinical

1 6

Flomax

Epoetin Beta

5 8

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

PROCRIT

WWim Janssens

Preclinical

1 10

Genotropin

EMD Serono

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

N/ARecruiting

Botox

NCT06075134

Clinical

Trials by Indication[1]

Botox1 trial

EMG-guided Botox Injection Versus Conventional Botox Injection in Gummy Smile Patients

Recruiting·—·N/A·NCT06075134·32 enrolled

Chronic Kidney Disease1 trial

Correction of Zinc Deficiency in Children With Chronic Kidney Disease and Kidney Transplant

Completed·HHamilton Health Sciences Corporation·Phase 3·NCT02126293·40 enrolled

Oral Lichen Planus1 trial

Oral Zinc Supplement as Adjunctive Therapy for Erosive Oral Lichen Planus

Completed·HHams Hamed Abdelrahman·N/A·NCT06042010·22 enrolled

Dialysis Patients1 trial

Effect of Zinc Suplementation on Serum Hemosystein Level in Hemodialysis Patients

Completed·SShiraz University of Medical Sciences·N/A·NCT01101217·100 enrolled

Chronic1 trial

Study to Evaluate the Possible Antifibrotic Effect of Zinc Sulphate in Chronic HCV Patient Receiving Direct Acting Anti-viral Therapy.

Completed·TTanta University·Phase 3·NCT05465434·50 enrolled

3 more indications

Botulinum Toxin1 trial

Testing the Effect of Zinc Supplementation to Improve the Treatment Effect of Botulinum Toxin for Oculofacial Spasm

Unknown status·SSt. Joseph's Healthcare Hamilton·N/A·NCT01546805·40 enrolled

Diarrhea1 trial

Zinc Supplementation and Severe and Recurrent Diarrhea

Completed·HHormozgan University of Medical Sciences·N/A·NCT01306097·100 enrolled

Unspecified1 trial

Zincoxide-propolis vs Zincoxide-eugenol Pulpectomy

Unknown status·—·Phase 1·NCT05230797·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Zinc Supplement. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zinc Supplement compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zinc Supplement. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hamilton Health Sciences Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHamilton Health Sciences Corporation

Zinc Supplement

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Botox1 trial

Chronic Kidney Disease1 trial

Oral Lichen Planus1 trial

Dialysis Patients1 trial

Chronic1 trial

Botulinum Toxin1 trial

Diarrhea1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News